97296 ⎘
Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Metalloproteinase binding proteins
#4802Compositions and methods for diagnosing and treating prostate cancer
#4803Treatment of interstitial cystitis
#4804Anti MIF antibodies
#4805Targeted binding agents directed to KDR and uses thereof—035
#4806Polypeptides, antibody variable domains and antagonists methods for
#4807De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#4808Antibodies and related molecules that bind to 161P2F10B proteins
#4809DKK-1 antibodies
#4810Anti-FcRH5 antibodies and immunoconjugates and methods of use
#4811ANTI-IGF-I RECEPTOR ANTIBODIES
#4812Dual Variable Domain Immunoglobulins and Uses Thereof
#4813TRIVALENT, BISPECIFIC ANTIBODIES
#4814Bispecific Anti ErbB3 / Anti cMet Antibodies
#4815Multispecific antibodies comprising full length antibodies and single chain fab fragments
#4816Antibodies to insulin-like growth factor I receptor
#4817Multispecific anti-HER antibodies
#4818POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS
#4819ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
#4820Bispecific Anti ErbB1 / Anti c Met Antibodies
#4821Bispecific Anti ErbB2 / Anti cMet Antibodies
#4822Antibody molecules having specificity for human OX40
#4823METHODS FOR SELECTING PROTEASE RESISTANT POLYPEPTIDES
#4824Modulating immune responses
#4825REVERSIBLY INHIBITED ANTIBODIES FOR IMMUNE CELL STIMULATION
#4826OPSONIC MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR LIPOTEICHOIC ACID OF GRAM POSITIVE BACTERIA
#4827Nucleic acid molecules encoding antibodies to M-CSF
#4828Anti-FGFR3 antibodies and methods using same
#4829Anti-NKG2A antibodies and uses thereof
#4830POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS
#4831Immunoglobulin constant region FC receptor binding agents
#4832COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
#4833JOINT DESTRUCTION BIOMARKERS FOR ANTI-IL-17A THERAPY OF INFLAMMATORY JOINT DISEASE
#4834Detection of CXADR protein for diagnosis of kidney cancer
#4835Anti-glypican-3 antibody having improved kinetics in plasma
#4836Method of treating disorders of the cardiovascular system and a pharmaceutical agent
#4837METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES
#4838HUMAN ANTIBODIES AGAINST HUMAN FAS AND THEIR USE
#4839Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3
#4840SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT
#4841Cytokine zalpha11 ligand antibodies
#4842Polynucleotides encoding humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
#4843PDGFR BETA-SPECIFIC INHIBITORS
#4844Method of treating a pathological syndrome and a pharmaceutical agent
#4845METHODS OF TREATING BRAIN TUMORS WITH ANTIBODIES
#4846WISP POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
#4847Anti-CD79B antibodies and immunoconjugates and methods of use
#4848Interleukin-6 receptor binding polypeptides
#4849Humanized antibodies that bind to CD19 and their uses
#4850Methods of treating dementia using a GM-CSF antagonist
#4851IMMUNOLIPOSOME INDUCING APOPTOSIS INTO CELL EXPRESSING DEATH DOMAIN-CONTAINING RECEPTOR
#4852OVR110 Antibody Compositions and Methods of Use
#4853Monoclonal antibodies against glypican-3
#4854TREATMENT OF CHRONIC INFLAMMATORY CONDITIONS
#4855SYSTEM AND METHOD FOR FORMING AN INTERLOCKING SOLAR PANEL ARRAY
#4856INHIBITORS FOR GROWTH HORMONE AND RELATED HORMONES, AND METHODS OF USE THEREOF
#4857Method of treating a disorder or condition of viral etiology
#4858Anti-PD-L1 antibodies, compositions and articles of manufacture
#4859ANTIBODIES TO EGFL7 AND METHODS FOR THEIR USE
#4860Cripto blocking antibodies and uses thereof
#4861TARGETED BINDING AGENTS DIRECTED TO CD105 AND USES THEREOF
#4862Anti-IGF antibodies
#4863Anti-system ASC amino acid transporter 2 (ASCT2) antibody
#4864Ligands of HVEM for treating hematologic malignancies
#4865Method of modulating the activity of functional immune molecules
#4866Method of inhibition of vascular development using an antibody
#4867Pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma
#4868Humanized L243 antibodies
#4869Humanized anti-HLA-DR antibodies
#4870Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
#4871Antibodies to human ErbB4
#4872Use of Hepatitis B X-Interacting Protein (HBXIP) in Modulation of Apoptosis
#4873ANTI CD37 ANTIBODIES
#4874Anti-VEGF antibodies
#4875Antibodies to human IL-22
#4876Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
#4877Truncated BAFF receptors
#4878Method for determining MIF content
#4879Antibodies directed to HER-3 and uses thereof
#4880CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#4881TES7 and antibodies that bind thereto
#4882Modulation of NKG2D
#4883HEPATOCYTE GROWTH FACTOR RECEPTOR SPLICE VARIANTS AND METHODS OF USING SAME
#4884Tweak receptor
#4885Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
#4886Methods of Treating Autoimmune Diseases
#4887Destruction of tumor cells by trifunctional bispecific antibodies with low to medium expression levels of tumor-associated target antigens
#4888Covalent diabodies and uses thereof
#4889Hepatocyte growth factor (HGF) binding proteins
#4890Hepatocyte growth factor (HGF) binding proteins
#4891METHODS AND COMPOSITIONS FOR TREATING DISEASES TARGETING MABA1
#4892Superagonistic anti-CD28 antibodies
#4893Therapeutic use of anti-CS1 antibodies
#4894Humanized GM-CSF antibodies
#4895Monoclonal antibodies against claudin-18 for treatment of cancer
#4896Engineered anti-TSLP antibody
#4897Method for administering homeopathically potentized antibody
#4898ANTI-EGFR ANTIBODIES
#4899ALTERED BR-3 BINDING POLYPEPTIDES
#4900USE OF EphA4 AND MODULATOR OF EphA4 FOR DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER
#4901Antibodies against human angiopoietin 2
#4902Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates
#4903Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
#4904Antibodies to ErbB2
#4905Treatment with anti-alpha2 integrin antibodies
#4906RECOMBINANT ANTIBODIES AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)
#4907OSTEOPONTIN FUNCTIONAL EPITOPES, MONOCLONAL ANTIBODIES AGAINST THE EPITOPES AND USES THEREOF
#4908HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF
#4909Anti-IGF antibodies
#4910CELL DEATH INDUCER
#4911KIM-1 antibodies for treatment of TH2-mediated conditions
#4912Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
#4913Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
#4914FGFR4 Promotes Cancer Cell Resistance in Response to Chemotherapeutic Drugs
#4915Anti-CD98 antibody
#4916CD161 ligand, pilar, for modulating activation and proliferation of T cells
#4917Use of Antibody Conjugates
#4918Ovr115 antibody compositions and methods of use
#4919METHODS AND COMPOSITIONS FOR TREATING CANCER
#4920Methods of treating colitis involving IL-13 and NK-T cells
#4921Humanized anti-IL-6 antibodies
#4922Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
#4923Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
#4924ANTAGONIST OX40 ANTIBODIES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
#4925OVR110 antibody compositions and methods of use
#4926Monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II)
#4927ANTIBODIES RECOGNIZING OXYGEN-REGULATED PROTEIN 150 EXPRESSED ON CANCER CELLS AND METHODS OF USING SAME
#4928COMPOSITIONS AND METHODS FOR THE INHIBITION OF CRIPTO / GRP78 COMPLEX FORMATION AND SIGNALING
#4929METHODS OF MODULATING HVEM, BTLA AND CD160 CIS COMPLEX RESPONSE OR SIGNALING ACTIVITY WITH SOLUBLE LIGHT POLYPEPTIDE SEQUENCES
#4930Polynucleotide encoding an anti-FGF19 antibody
#4931Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
#4932c-Met antibodies
#4933Antibodies against human interleukin-13 and uses therefor
#4934COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT
#4935BSL2v1c2 polypeptides
#4936Compositions and Methods for Treating Pancreatic Tumors
#4937Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
#4938AMINO ACID SEQUENCES DIRECTED AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CONDITIONS AND DISEASES CHARACTERIZED BY EXCESSIVE AND/OR PATHOLOGICAL ANGIOGENESIS OR NEOVASCULARIZATION
#4939VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS
#4940Anti-TGF-beta receptor II antibodies
#4941Antibodies Against Cancer
#4942Antibodies inhibiting c-Met dimerization and uses thereof
#4943Soluble IL-17RCx4 and fusion proteins thereof
#4944Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
#4945Monoclonal antibodies for treatment of cancer
#4946Anti-NGF antibodies and methods using same
#4947IL-4 RECEPTOR AND IL-13 AS PROGNOSTIC MARKERS FOR COLON AND PANCREAS TUMORS
#4948Methods for mediating fibrotic response
#4949Bispecific anti-VEGF/anti-ANG-2 antibodies
#4950ENGINEERED ANTI-IL-23P19 ANTIBODIES
#4951COMBINATION THERAPY
#4952ANTI-IL-20, ANTI-IL-22 AND ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
#4953Antibodies to notch receptors
#4954ADAM-9 modulators
#4955Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
#4956Antibodies against RAMP3
#4957Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
#4958Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
#4959Compositions and methods for modulating responses mediated or associated with BTLA activity
#4960Antibodies and methods for making and using them
#4961Human monoclonal antibodies that bind CXCR4
#4962Anti-IGF-1R Antibodies and Uses Thereof
#4963ANTIBODIES AGAINST A PROTEIN ENTITLED 161P2F10B
#4964IMMUNOGLOBULIN VARIANTS AND USES THEREOF
#4965Anti-IGR-1R antibodies and uses thereof
#4966MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR
#4967Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
#4968COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT
#4969PEPTIDE THERAPEUTICS THAT BIND VEGF AND METHODS OF USE THEREOF
#4970POTENT CELL-BINDING AGENT DRUG CONJUGATES
#4971VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS
#4972M-CSF-specific monoclonal antibody and uses thereof
#4973Remedy For Chemotherapy-Resistant Cancer Containing HLA Class I-Recognizing Antibody as the Active Ingredient and Use of the Same
#4974Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies
#4975Anti-JAM-A antibodies
#4976PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS
#4977Antibodies that bind to EphA2 and methods of use thereof
#4978ANTIBODY AND USES THEREOF
#4979Enhancement of B cell proliferation by IL-15
#4980BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES
#4981Modified glycoproteins and uses thereof
#4982Modified host cells and uses thereof
#4983N-Glycans and Uses Thereof
#4984Methods for generating host cells
#4985Methods of reducing T cell-mediated immune responses with multimeric P-selectin and/or E-selectin compounds
#4986METHODS OF TREATING DISEASES WITH ANTI-VEGF ANTIBODIES
#4987GITR LIGAND AND GITR LIGAND-RELATED MOLECULES AND ANTIBODIES AND USES THEREOF
#4988Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
#4989DcR3 polypeptide, A TNFR homolog
#4990Dual variable domain immunoglobulins and uses thereof
#4991METHODS FOR SOLUBLE ZALPHA11 CYTOKINE RECEPTORS
#4992Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
#4993ANTIBODY COMPOSITIONS, METHODS FOR TREATING NEOPLASTIC DISEASE AND METHODS FOR REGULATING FERTILITY
#4994Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
#4995Monoclonal antibodies
#4996PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT
#4997SPECIFIC BINDING PROTEINS AND USES THEREOF
#4998ANTIBODIES AGAINST ERBB3 AND USES THEREOF
#4999Sialoadhesin factor-2 antibodies
#5000Prostate stem cell antigen (PSCA) variants and subsequences thereof
#5001CELLULAR RECEPTOR FOR ANTIPROLIFERATIVE FACTOR
#5002METHODS FOR PREVENTING HEMATOLOGICAL MALIGNANCIES AND GRAFT VERSUS HOST DISEASE BY ANTI-CD3 PRECONDITIONING
#5003EPHA2 receptor antagonist antibodies
#5004Fully human monoclonal antibodies to IL-13
#5005Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
#5006NOVEL ANTIBODIES AGAINST IGF-IR
#5007Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukaemia
#5008ANTIBODY VARIANTS
#5009ANTI HER2/NEU ANTIBODY
#5010ANTIBODIES AND RELATED MOLECULES THAT BIND TO 58P1D12 PROTEINS
#5011Anti-human IL-21 monoclonal antibodies
#5012Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient
#5013Compositions and methods for promoting or inhibiting angiogenesis
#5014Antibodies to c-Met
#5015TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASE
#5016HUMAN EPO MIMETIC HINGE CORE MIMETIBODIES, COMPOSITIONS, METHODS AND USES FOR PREVENTING OR TREATING GLUCOSE INTOLERANCE RELATED CONDITIONS ON RENAL DISEASE ASSOCIATED ANEMIA
#5017Compositions and methods for binding lysophosphatidic acid
#5018GAINAC SPECIFIC BINDING MOLECULES AND USES THEREOF
#5019Compositions and Methods for Controlling Tissue Factor Signaling Specificity
#5020Antibodies that specifically bind to Aβ oligomers and uses thereof
#5021Compositions monovalent for CD28 binding and methods of use
#5022Antibodies against vascular endothelial growth factor receptor-1
#5023CONDITIONED CELL IMMUNIZATION
#5024COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF
#5025Nucleic acids encoding antibodies against PD-1
#5026outer membrane protein-106 polypeptide, gene sequence and uses thereof
#5027High affinity human antibodies to human IL-4 receptor
#5028Methods and compositions for inhibiting the growth of hematopoietic malignant cells
#5029METHODS FOR DIAGNOSING AND TREATING CANCER
#5030Functional role of adrenomedullin (AM) and the gene related product (PAMP) in human pathology and physiology
#5031Compositions and methods of use for therapeutic antibodies
#5032THERAPEUTIC APPLICATIONS OF NONCOVALENT DIMERIZING ANTIBODIES
#5033Method for making humanized antibodies
#5034Methods of using antibodies against human IL-22
#5035METHODS AND COMPOSITIONS FOR THE UTILIZATION AND TARGETING OF OSTEOMIMICRY
#5036Camptothecin-binding moiety conjugates
#5037Anti-IGF-I receptor antibodies, DNAs, vectors, host cells and genetic constructs
#5038Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
#5039AGENT FOR PREVENTING/TREATING CANCER
#5040Fibroblast growth factor receptor 3 (FGFR3) binding proteins
#5041Anti-human dlk-1 antibody showing anti-tumor activity in vivo
#5042ANTIBODY VACCINE CONJUGATES AND USES THEREFOR
#5043M-csf specific monoclonal antibody and uses thereof
#5044ANTI-FN14 ANTIBODIES AND USES THEREOF
#5045TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
#5046Method for the treatment of inflammatory disorders
#5047Compositions and methods for the diagnosis and treatment of tumor
#5048Method of treating pulmonary disease by administering an antibody to G-CSF receptor
#5049Diagnosis and treatment of cancer using anti-EREG antibody
#5050Compositions and methods for the diagnosis and treatment of tumor
#5051Soluble CTLA4 mutant molecules and uses thereof
#5052Antibody specifically binding to DR5 and composition for preventing or treating cancers comprising the same
#5053TREATMENT OF METASTATIC BREAST CANCER
#5054Methods of using death receptor ligands and cd20 antibodies
#5055AUTOPHILIC ANTIBODIES AND METHOD OF MAKING THE SAME
#5056DEGRADED AGONIST ANTIBODY
#5057CD40 ANTIBODY FORMULATION AND METHODS
#5058Dual variable domain immunoglobulins and uses thereof
#5059Human antibodies that bind human IL-12 and methods for producing
#5060BINDING PARTNERS WITH IMMUNOGLOBULIN DOMAINS MODIFIED TO HAVE EXTENDED HALF-LIFE
#5061TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES
#5062Anti-CD38 antibodies for the treatment of cancer
#5063Monoclonal antibodies to basic fibroblast growth factor
#5064Antagonist anti-CD40 antibody pharmaceutical compositions
#5065METHODS FOR TREATING CANCER BY INHIBITING WNT SIGNALING
#5066Dual variable domain immunoglobulins and uses thereof
#5067METHODS OF USING CD40 BINDING AGENTS
#5068Antibodies as T cell receptor mimics, methods of production and uses thereof
#5069ANTI-CD8 ANTIBODIES BLOCK PRIMING OF CYTOTOXIC EFFECTORS AND LEAD TO GENERATION OF REGULATORY CD8+ T CELLS
#5070Therapeutic compositions and methods
#5071Cancerous Disease Modifying Antibodies
#5072Peptides for treatment and diagnosis of autoimmune disease
#5073CONTROL CIRCUITRY FOR PROVIDING AN INTERFACE BETWEEN CONNECTABLE TERMINAL AND PERIPHERAL DEVICE CIRCUITRY
#5074Multivalent fibronectin based scaffold domain proteins
#5075Anti-hDlk-1 antibody having an antitumor activity in vivo
#5076Interleukin-21 receptor binding proteins
#5077Methods of treatment utilizing binding proteins of the interleukin-21 receptor
#5078Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
#5079Antibody neutralizers of human granulocyte macrophage colony stimulating factor
#5080HERV-K ANTIGENS, ANTIBODIES, AND METHODS
#5081ANTI-FLT3 ANTIBODIES
#5082Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
#5083CD33-SPECIFIC SINGLE-CHAIN IMMUNOTOXIN AND METHODS OF USE
#5084Treatment method using anti-PD-L1 antibody
#5085THERAPEUTIC COMBINATIONS OF ANTI-IGF-1R ANTIBODIES AND OTHER COMPOUNDS
#5086MODULATING ANGIOGENESIS
#5087Antibodies against ErbB3 and uses thereof
#5088Anti-IL-6 antibodies, compositions, methods and uses
#5089BARB4 TARGET, ANTIBODY DESIGNATED BARB4, BARB4 RELATED ANTIBODIES, AND METHODS OF MAKING AND USING SAME
#5090Methods and compositions for treating allergic diseases
#5091Cripto blocking antibodies and uses thereof
#5092Method for producing human antibodies to a self physiological receptor by site-directed in vitro immunization of human lymphocytes
#5093HER2 antibody composition
#5094Anti-PECAM Therapy for Metastasis Suppression
#5095Compositions and methods relating to anti IGF-1 receptor antibodies
#5096Cripto Blocking Antibodies and Uses Thereof
#5097Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene
#5098CD 40 Binding Molecules and CTL Pepetides for Treating Tumors
#5099Antibodies and methods for making and using them
#5100Humanized anti-TGF-beta antibodies